STAGE IIIB NON-SMALL CELL LUNG CANCER
Clinical trials for STAGE IIIB NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIB NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for STAGE IIIB NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for tough lung cancer
Disease control CompletedThis study tested a combination of two drugs—TG4010 (a vaccine that helps the immune system attack cancer) and nivolumab (an immunotherapy that removes cancer's brakes on immune cells)—in 13 people with advanced non-small cell lung cancer who had already tried other treatments. T…
Matched conditions: STAGE IIIB NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Megan Daly, MD • Aim: Disease control
Last updated May 17, 2026 05:48 UTC
-
Could a diabetes drug boost lung cancer treatment?
Disease control CompletedThis study looked at whether adding metformin (a common diabetes medicine) to standard chemotherapy and radiation therapy helps people with stage III non-small cell lung cancer live longer without the cancer growing. About 170 people took part. The goal was to see if the combinat…
Matched conditions: STAGE IIIB NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 17, 2026 05:46 UTC
-
Precision radiation plus immunotherapy shows promise for tough lung cancers
Disease control CompletedThis study tested a new way to treat advanced lung cancer (stages IIB to IIIC) that cannot be removed with surgery. It combined MRI-guided, high-dose radiation with standard chemotherapy and an immunotherapy drug called durvalumab. The goal was to see if this approach is safe and…
Matched conditions: STAGE IIIB NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 17, 2026 05:37 UTC
-
Experimental combo shows promise against tough cancers
Disease control CompletedThis study tested a combination of two drugs—sEphB4-HSA and pembrolizumab—in 42 people with advanced non-small cell lung cancer or head & neck cancer that had spread or come back. The goal was to see if the combo could shrink tumors better than standard treatments. Participants h…
Matched conditions: STAGE IIIB NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 17, 2026 05:34 UTC
-
New drug cocktail shows promise for tough lung cancers
Disease control CompletedThis study tested a combination of two drugs, auranofin and sirolimus, in 29 people with advanced or recurrent lung cancer who had run out of standard treatment options. The goal was to find the best dose and see if the combo could slow cancer growth. The trial focused on safety …
Matched conditions: STAGE IIIB NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Triple threat: immunotherapy plus chemo and radiation shows promise in lung cancer trial
Disease control CompletedThis early-stage trial tested the safety and best dose of adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel and carboplatin) and radiation for people with stage II to IIIB non-small cell lung cancer. The goal was to see if this combination could be …
Matched conditions: STAGE IIIB NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New combo therapy tested for hard-to-treat lung cancer
Disease control CompletedThis early-stage study tested a new drug called ONO-7475 combined with the standard drug osimertinib in 78 people with advanced EGFR-mutant non-small cell lung cancer that could not be treated with radiation. The main goal was to check safety and find the right dose. Researchers …
Matched conditions: STAGE IIIB NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 05, 2026 11:56 UTC